Inflammatory/Immune

Displaying 1 - 10 of 10


Traveler's Diarrhea Vaccine for Enterotoxigenic E. coli (ETEC)

Vanderbilt researchers are developing a novel vaccine for preventing enterotoxigenic Escherichia coli (ETEC) infection of the gut which causes traveler's diarrhea and childhood death in developing countries. The vaccine uses colonization surface antigens and their constituent proteins to generate an immune response. This prevents infection by blocking the ability of bacteria to adhere to the intestinal mucosa. Mice treated with this vaccine showed significantly reduced disease and bacterial colonization compared to control. Preclinical development of this vaccine is ongoing and includes testing of different adjuvants and routes of administration. ETEC is a leading cause of gastrointestinal disease in developing countries affecting both residents and visitors. Residents in particular are primarily children who suffer high morbidity and mortality from the dehydrating effects of the illness. Visitors include the approximately 800 -- 1000 million people who travel to developing countries each year with 20 -- 60 % of them developing this illness. A commercially available vaccine to inoculate residents and travelers against ETEC would represent a significant opportunity to satisfy an unmet need and improve human health.


Licensing Contact

Jody Hankins

615.322.5907

Anti-human Myeloid Cell Nuclear Differentiation Monoclonal Antibody

The antibody is a rat IgG1 monoclonal, clone 3C1.


Licensing Contact

Jody Hankins

615.322.5907
Research Tools
Antibody
Inflammatory/Immune

Anti-Armadillo Repeat Gene Deleted in Velo-cardiofacial Syndrome Monoclonal Antibody

This research targets ARVCF.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Albert Reynolds
Research Tools
Antibody

Floxed Prostaglandin D2 Receptor Alleles

This research targets DP1.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Richard Breyer
Research Tools
Animal Model

New NSAIDs Derivatives for Cancer Treatment - Protective and Less Toxic, Targeting PPAR gGamma

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely-used anti-inflammatory and anti-pyretic therapeutic agents to treat human diseases. However, long-term use of NSAIDs comes with risks. Many NSAIDs are COX-1 inhibitors, which are associated with significant GI toxicities. The Marnett Lab at Vanderbilt University has developed new derivatives of NSAIDs that retain their protective effects but do not cause debilitating and potentially fatal toxicities.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics

Carboxylic Acid Amides as Selective COX-2 Inhibitors

A method of treating animals having cancer by administration of secondary amide derivatives of various COOH-containing drugs, such as COOH-containing NSAIDs, for instance, indomethacin.


Licensing Contact

Mike Villalobos

615.322.6751

Novel Esters and Amides Derived from Indolealkanol and Indolealkylamines as Selective Cyclooxygenase-2 (Cox-2) Inhibitors

A compound of the formula ##STR1## where: n, and X are as defined in the specification, and the compound possesses selectivity for inhibition of cyclooxygenase-2.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Inflammatory/Immune

Lipoxygenase Proteins and Nucleic Acids

Isolated and purified lipoxygenase proteins and nucleic acids are described. Particularly, a novel human 15(S) lipoxygenase (15-Lox-2) protein and cDNA and a cDNA for mouse 8S-lipoxygenase are described. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also described, along with methods of producing each. Isolated and purified antibodies to 15-Lox-2 and 8-Lox, and methods of producing the same, are also described.


Licensing Contact

Janis Elsner

615.343.2430

Inventors

Alan Brash

EP4 Transgenic Mice

EP4 Transgenic Mice are part of the Vanderbilt Research Tools Catalog.


Licensing Contact

Karen Rufus

615.322.4295

MMP-7 Null Mice

The only MMP-7-null mouse that has been generated. Used to determine biological function of MMP-7. Mice have been used in more than 10 publications at this point, and will be distributed by a commercial vendor in the near future.


Licensing Contact

Karen Rufus

615.322.4295